When a 4-year-old patient was diagnosed with a rare type of Ewing sarcoma, her team of pediatric and surgical oncologists came together with a plan that deviated slightly from the traditional treatment paradigm. This approach, her physicians say, allowed them to salvage significant anatomy.
A new study led by Cleveland Clinic researchers suggests that the small molecule ONC201 has promise as a less toxic treatment for pheohromocytomas/paragangliomas, and possibly other rare neuroendocrine tumors as well.
Results of a Phase 2 trial offer much-needed guidance to clinicians treating a rare and aggressive form of sarcoma. Dr. Peter Anderson explains.
With greater precision made possible through image guidance, radiotherapy combined with new chemotherapeutics means radiation will be desirable instead of feared in childhood cancer therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
This noted pediatric osteosarcoma expert shares his proudest discovery and a few reflections on patient care as he settles in at Cleveland Clinic Children’s.